Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure

NCT07486297 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-06-30
Last updated
2026-06-25

Condition(s) studied

Implantation Failure

Investigational drug(s) / intervention(s)

Placebo GroupAcupuncture group

Placebo Group: nonpenetrating placebo needles

Acupuncture group: indwelling intradermal needles

Study summary

To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos). 2. Age: 20 to 40 years old. 3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET). 4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC). 5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation. Exclusion Criteria: 1. Individuals planning to undergo preimplantation genetic diagnosis (PGD). 2. Recipients of egg donations. 3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms). 4. Patients with known embryo-related factors leading to implantation failure. 5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on). 6. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more). 7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months. 8. Individuals with untreated hydrosalpinx; 9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/m2. 10. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.

Primary outcome measure(s)

  • clinical pregnancy — 1 year
    defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07486297 on ClinicalTrials.gov ↗ ← All trials in China